Connect with us

Health

Monoclonal antibodies against MERS coronavirus show promise in phase 1 trial – Medical Xpress

A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…

Published

on

Article feature image

A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Vaccine overdose doctor was sanctioned before – Morning Bulletin
Article feature image
Covid-19: India in a ‘delicate phase’ of its coronavirus battle as cases surge – BBC News